• Fe3O4@ZIF-8 for Jaw Osteomyelitis

  2026-08-21

  The reference study develops Fe3O4@ZIF-8 core–shell nanoparticles that combine pH-responsive Zn2+ release for antibacterial action with magnetically supported bone regeneration. Its significance lies in addressing persistent infection and infected bone defects within one biomaterial platform, while also identifying bacterial membrane disruption and heat-shock-response inhibition as complementary antibacterial mechanisms.

• BMN 673 (Talazoparib) Experimental Workflow

  2026-08-20

  BMN 673 (Talazoparib) combines subnanomolar PARP1/2 inhibition with strong PARP-DNA complex trapping, making it a useful probe for DNA repair deficiency targeting. This guide translates the mechanism into practical workflows for homologous recombination-deficient models, HCC spliceosome studies, and small cell lung cancer research, with controls and troubleshooting built in.

• Age-Related CMA Decline Drives Skeletal Myopathy

  2026-08-20

  The reference study establishes chaperone-mediated autophagy (CMA) as an active regulator of skeletal muscle maintenance rather than a passive lysosomal pathway. Using reporter, genetic, proteomic, physiological, and human-tissue approaches, it connects age-related CMA loss to SERCA turnover, calcium dysregulation, muscle weakness, and progressive myopathy.

• SR 11302: AP-1 Transcription Factor Inhibitor

  2026-08-19

  SR 11302 is an AP-1 transcription factor inhibitor that suppresses AP-1 activity without activating RAR or RXR receptors. Product data support selective antiproliferative effects in several cancer cell models and reduced carcinogen-induced papilloma formation in AP-1-luciferase transgenic mice.

• Fluorinated CXCR4 Inhibitor A1 in Colorectal Cancer

  2026-08-19

  Khorramdelazad et al. evaluated A1, a fluorinated CXCR4 inhibitor, using molecular dynamics, CT-26 cell assays, and a BALB/c colorectal cancer model. A1 showed stronger computational binding, reduced tumor-cell proliferation and migration, altered immunosuppressive tumor-microenvironment features, and outperformed AMD3100 in several in vivo endpoints, while remaining a preclinical candidate requiring further validation.

• ERAD-Hijacking Chimeras for TM Protein Degradation

  2026-08-18

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule targeted protein degradation platform that recruits the ER-associated degradation pathway to eliminate transmembrane proteins. By using desonide as a SYVN1-binding warhead, the study achieved highly potent PD-L1 degradation, enhanced tumor suppression in vivo, and an initial extension to mutant HTT degradation.

• TTP–WTAP–m6A Axis in Schistosomiasis Fibrosis

  2026-08-18

  A 2026 PLOS Pathogens study identifies tristetraprolin (TTP) as an antifibrotic regulator in Schistosoma japonicum-induced liver fibrosis. Its central finding is that TTP promotes WTAP transcription through SMAD2/3, increasing m6A-dependent destabilization of TGF-β1 mRNA and limiting hepatic stellate cell activation.

• AZD0156: A Better Framework for ATM Assays

  2026-08-17

  AZD0156 is a selective ATM kinase inhibitor for studying how DNA damage signaling, repair, and checkpoint control shape cancer-cell responses. This guide adds an assay-design framework that connects target engagement with functional and translational readouts.

• Acridine Orange hydrochloride: Practical Staining Guide

  2026-08-17

  Acridine Orange hydrochloride is a cell- and organelle-permeable fluorescent nucleic acid dye for distinguishing DNA-associated green fluorescence from RNA or single-stranded nucleic acid-associated red fluorescence. It is suitable for cell cycle analysis, apoptosis detection, and flow-based nucleic acid workflows, but assay-specific settings must be validated and prepared solutions should not be stored long term.

• Phillygenin in Diabetic Nephropathy: Mechanistic Evidence

  2026-08-16

  A 2025 Phytomedicine study identifies phillygenin as a preclinical candidate for diabetic nephropathy and connects its renal protective effects with suppression of TLR4/MyD88/NF-κB signaling and restoration of PI3K/AKT/GSK3β-associated survival signaling. Its integrated podocyte, transcriptomic, biochemical, and db/db mouse experiments provide a useful framework for studying inflammation, apoptosis, and proteinuria in diabetic kidney disease.

• Diuron Workflows for Plant and Toxicology Research

  2026-08-15

  Diuron supports two complementary research paths: controlled photosynthesis-inhibitor assays in plant systems and mechanistic toxicology studies in mammalian cells. This workflow-focused guide connects solvent handling, dose-response design, JAK2/STAT1 validation, and troubleshooting for more reproducible experiments.

• 7ACC2: Monocarboxylate Transporter 1 Inhibitor

  2026-08-14

  7ACC2 is a nanomolar carboxycoumarin tool for separating lactate uptake, pyruvate transport, and downstream metabolic stress in tumor models. Its value extends beyond viability testing: carefully staged transport assays can connect cancer-cell metabolism with the immunosuppressive tumor microenvironment while preserving clear experimental boundaries.

• Plerixafor (AMD3100): CXCR4 Research Guide

  2026-08-14

  Plerixafor, also called AMD3100, is a small-molecule CXCR4 antagonist that disrupts CXCL12/SDF-1 signaling. It supports mechanistic studies of cancer metastasis inhibition, hematopoietic stem cell mobilization, neutrophil trafficking, and WHIM syndrome treatment research.

• BMS-345541 hydrochloride: IKK Inhibitor Workflows

  2026-08-13

  BMS-345541 hydrochloride enables selective NF-κB pathway interrogation across inflammation research, T-cell acute lymphoblastic leukemia models, and translational airway-stent assays. This guide connects pathway-level target engagement with practical dose design, conditioned-medium experiments, apoptosis measurements, and troubleshooting for solubility and timing artifacts.

• Dihydrotestosterone Workflows for AR Research

  2026-08-13

  Dihydrotestosterone (DHT) provides a direct, tunable way to interrogate androgen receptor signaling, from EGFR–AKT responses in bladder cancer cells to muscle and neurodegeneration models. This workflow-focused guide connects concentration control, phosphoprotein timing, and orthogonal validation with the androgen and TGF-β/Smad findings reported in a recent prostate research study.

11591 records 1/773 page Next 12345 下5页 Last page